newsfilter
← Latest News
GlobeNewswire·

BeautyHealth Reports Full Year and Fourth Quarter 2025 Financial Results

SKIN
  • The Beauty Health Company reported full-year 2025 net sales of $300.8 million, a 10.0% decrease from $334.3 million in 2024, with fourth-quarter 2025 net sales of $82.4 million, a 1.3% decrease from the prior year.
  • Delivery systems sales declined significantly in 2025, with 3,726 units sold compared to 4,907 in 2024, while consumables net sales increased to $212.7 million for the full year from $208.9 million.
  • Gross margin improved to 65.3% for the full year 2025 from 54.5% in 2024, driven by lower inventory charges and a favorable shift toward consumable sales.
  • Adjusted operating expenses for 2025 totaled $160.0 million, down from $194.9 million in 2024, primarily due to reduced personnel-related expenses and marketing spend.
  • The company reduced its net loss to $9.5 million for 2025 from $29.1 million in 2024, while Adjusted EBITDA increased to $45.1 million from $12.3 million.
  • Cash, cash equivalents, and restricted cash decreased to approximately $233 million as of December 31, 2025, from $370 million in 2024, largely due to the repurchase of convertible senior notes.
  • In February 2026, the company repurchased $21.3 million principal amount of 2026 Notes for $20.2 million at a weighted-average price of 94.875%.
  • The company has discontinued direct sales in China, transitioning the market to a distributor partner during the second quarter of 2025.
  • First-quarter 2026 net sales are projected between $63 million and $68 million, with Adjusted EBITDA guidance of $3.5 million to $5.5 million.
  • Full-year 2026 net sales are guided between $285 million and $305 million, with Adjusted EBITDA expected to range from $35 million to $45 million.
  • The company expects first-half 2026 revenue to be modestly below the first half of 2025, anticipating improvement in the second half as commercial initiatives take hold.
  • The active install base stood at 36,026 systems as of December 31, 2025, representing an increase from 34,735 in the prior year.
  • A conference call to review the results is scheduled for March 12, 2026, at 4:30 p.m. ET, with a live webcast available via the company's investor relations website.